Scolaris Content Display Scolaris Content Display

Agentes estimulantes de la eritropoyesis de acción corta para el tratamiento de la anemia en pacientes de prediálisis

Appendices

Appendix 1. Electronic search strategies

Database

Search terms

CENTRAL

  1. MeSH descriptor: [Renal Insufficiency] this term only

  2. MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees

  3. MeSH descriptor: [Kidney Diseases] this term only

  4. "chronic kidney" or "chronic renal":ti,ab,kw (Word variations have been searched)

  5. CKF or CKD or CRF or CRD:ti,ab,kw (Word variations have been searched)

  6. pre‐dialy* or predialy*:ti,ab,kw (Word variations have been searched)

  7. MeSH descriptor: [Uremia] explode all trees

  8. uremi* or uraemi*:ti,ab,kw (Word variations have been searched)

  9. {or #1‐#8}

  10. MeSH descriptor: [Anemia] explode all trees

  11. anemi* or anaemi*:ti,ab,kw (Word variations have been searched)

  12. {or #10‐#11}

  13. MeSH descriptor: [Erythropoietin] this term only

  14. erythropoietin:ti,ab,kw (Word variations have been searched)

  15. epoetin:ti,ab,kw (Word variations have been searched)

  16. rhuepo:ti,ab,kw (Word variations have been searched)

  17. EPO:ti,ab,kw (Word variations have been searched)

  18. {or #13‐#17}

  19. {and #9, #12, #18}

MEDLINE

  1. Renal Insufficiency/

  2. exp Renal Insufficiency, Chronic/

  3. Kidney Diseases/

  4. (chronic kidney or chronic renal).tw.

  5. (CKF or CKD or CRF or CRD).tw.

  6. (pre‐dialy$ or predialy$).tw.

  7. exp Uremia/

  8. ur$emi$.tw.

  9. or/1‐8

  10. exp Anemia/

  11. (anemia or anaemia).tw.

  12. or/10‐11

  13. Erythropoietin/

  14. erythropoietin.tw.

  15. EPO.tw.

  16. rHuepo.tw.

  17. epoetin.tw.

  18. or/13‐17

  19. and/9,12,18

EMBASE

  1. Kidney Disease/

  2. Chronic Kidney Disease/

  3. Kidney Failure/

  4. Chronic Kidney Failure/

  5. Kidney dysfunction/

  6. (chronic kidney or chronic renal).tw.

  7. (CKF or CKD or CRF or CRD).tw.

  8. (pre‐dialy$ or predialy$).tw.

  9. or/1‐8

  10. exp anemia/

  11. (anemia or anaemia).tw.

  12. or/10‐11

  13. exp recombinant erythropoietin/

  14. erythropoietin.tw.

  15. EPO.tw.

  16. rHuepo.tw.

  17. epoetin.tw.

  18. or/13‐17

  19. and/9,12,18

Appendix 2. Risk of bias assessment tool

Potential source of bias

Assessment criteria

Random sequence generation

Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence

Low risk of bias: Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).

High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.

Unclear: Insufficient information about the sequence generation process to permit judgement.

Allocation concealment

Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment

Low risk of bias: Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web‐based, and pharmacy‐controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).

High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non‐opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear: Randomisation stated but no information on method used is available.

Blinding of participants and personnel

Performance bias due to knowledge of the allocated interventions by participants and personnel during the study

Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.

Unclear: Insufficient information to permit judgement

Blinding of outcome assessment

Detection bias due to knowledge of the allocated interventions by outcome assessors.

Low risk of bias: No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Unclear: Insufficient information to permit judgement

Incomplete outcome data

Attrition bias due to amount, nature or handling of incomplete outcome data.

Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.

High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; ‘as‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.

Unclear: Insufficient information to permit judgement

Selective reporting

Reporting bias due to selective outcome reporting

Low risk of bias: The study protocol is available and all of the study’s pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon).

High risk of bias: Not all of the study’s pre‐specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified; one or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear: Insufficient information to permit judgement

Other bias

Bias due to problems not covered elsewhere in the table

Low risk of bias: The study appears to be free of other sources of bias.

High risk of bias: Had a potential source of bias related to the specific study design used; stopped early due to some data‐dependent process (including a formal‐stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.

Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figures and Tables -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figures and Tables -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 1 Change in haemoglobin level.
Figures and Tables -
Analysis 1.1

Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 1 Change in haemoglobin level.

Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 2 Number reaching target haemoglobin.
Figures and Tables -
Analysis 1.2

Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 2 Number reaching target haemoglobin.

Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 3 Number of deaths.
Figures and Tables -
Analysis 1.3

Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 3 Number of deaths.

Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 4 Adverse events.
Figures and Tables -
Analysis 1.4

Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 4 Adverse events.

Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 1 Change in haemoglobin level.
Figures and Tables -
Analysis 2.1

Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 1 Change in haemoglobin level.

Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 2 Number reaching target haemoglobin.
Figures and Tables -
Analysis 2.2

Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 2 Number reaching target haemoglobin.

Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 3 Number of deaths.
Figures and Tables -
Analysis 2.3

Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 3 Number of deaths.

Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 4 Adverse events.
Figures and Tables -
Analysis 2.4

Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 4 Adverse events.

Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 1 Final haemoglobin.
Figures and Tables -
Analysis 3.1

Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 1 Final haemoglobin.

Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 2 Mean arterial BP.
Figures and Tables -
Analysis 3.2

Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 2 Mean arterial BP.

Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 3 Final creatinine levels.
Figures and Tables -
Analysis 3.3

Comparison 3 Epoetin alpha different doses given three times weekly, Outcome 3 Final creatinine levels.

Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 1 Final haemoglobin.
Figures and Tables -
Analysis 4.1

Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 1 Final haemoglobin.

Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 2 Number reaching target haemoglobin.
Figures and Tables -
Analysis 4.2

Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 2 Number reaching target haemoglobin.

Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 3 Number of deaths.
Figures and Tables -
Analysis 4.3

Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 3 Number of deaths.

Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 4 Adverse events.
Figures and Tables -
Analysis 4.4

Comparison 4 Epoetin alpha different doses given every four weeks, Outcome 4 Adverse events.

Comparison 5 Epoetin alpha IV versus subcutaneous administration, Outcome 1 Final haemoglobin.
Figures and Tables -
Analysis 5.1

Comparison 5 Epoetin alpha IV versus subcutaneous administration, Outcome 1 Final haemoglobin.

Comparison 6 Epoetin theta versus epoetin beta, Outcome 1 Final Hb.
Figures and Tables -
Analysis 6.1

Comparison 6 Epoetin theta versus epoetin beta, Outcome 1 Final Hb.

Comparison 6 Epoetin theta versus epoetin beta, Outcome 2 Mean weekly epoetin dose.
Figures and Tables -
Analysis 6.2

Comparison 6 Epoetin theta versus epoetin beta, Outcome 2 Mean weekly epoetin dose.

Comparison 6 Epoetin theta versus epoetin beta, Outcome 3 Deaths.
Figures and Tables -
Analysis 6.3

Comparison 6 Epoetin theta versus epoetin beta, Outcome 3 Deaths.

Comparison 6 Epoetin theta versus epoetin beta, Outcome 4 Adverse events.
Figures and Tables -
Analysis 6.4

Comparison 6 Epoetin theta versus epoetin beta, Outcome 4 Adverse events.

Summary of findings for the main comparison. Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis

Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis

Patient or population: anaemia in predialysis patients
Intervention: epoetin alpha every 2 weeks
Comparison: weekly

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with weekly

Risk with Epoetin alpha every 2 weeks

Change in Hb level

The mean change in Hb level was 0 g/dL

The mean change in Hb level in the intervention group was 0.19 g/dL lower (0.32 g/dL lower to 0.06 g/dL lower)

798 (4)

⊕⊕⊝⊝
LOW 1 2

downgraded for study limitations and indirectness

Number reaching target Hb

Study population

RR 0.96
(0.93 to 0.99)

798 (4)

⊕⊕⊝⊝
LOW 1 2

downgraded for study limitations and indirectness

960 per 1000

922 per 1000
(893 to 951)

Moderate

947 per 1000

910 per 1000
(881 to 938)

Number of deaths

Study population

RR 0.89
(0.38 to 2.07)

838 (4)

⊕⊕⊝⊝
LOW 1 3

downgraded for study limitations and imprecision

28 per 1000

24 per 1000
(10 to 57)

Moderate

22 per 1000

20 per 1000
(9 to 46)

Adverse events: RBC transfusions

Study population

RR 1.56
(0.71 to 3.45)

580 (3)

⊕⊕⊝⊝
LOW 3 4

downgraded for imprecision and study limitations

33 per 1000

52 per 1000
(23 to 114)

Moderate

37 per 1000

58 per 1000
(26 to 128)

Adverse events: hypertension

Study population

RR 0.85
(0.55 to 1.32)

838 (4)

⊕⊕⊕⊝
MODERATE 1

downgraded for study limitations

100 per 1000

85 per 1000
(55 to 132)

Moderate

95 per 1000

81 per 1000
(52 to 126)

Adverse events: thrombovascular events

Study population

RR 1.41
(0.67 to 3.00)

838 (4)

⊕⊕⊝⊝
LOW 1 3

downgraded for study limitations and imprecision

28 per 1000

39 per 1000
(18 to 83)

Moderate

27 per 1000

38 per 1000
(18 to 80)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; Hb: haemoglobin; RBC: red blood cells

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 allocation concealment unclear in 3 of 4 studies

2 surrogate outcome

3 few studies with low numbers and wide confidence

4 allocation concealment unclear in 2 of 3 studies

Figures and Tables -
Summary of findings for the main comparison. Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis
Summary of findings 2. Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis

Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis

Patient or population: anaemia in predialysis patients
Intervention: epoetin alpha every 4 weeks
Comparison: every 2 weeks

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with every 2 weeks

Risk with Epoetin alpha every 4 weeks

Change in Hb level

The mean change in Hb level was 0

The mean change in Hb level in the intervention group was 0.15g/dL lower (0.41 g/dL lower to 0.1g/dL more)

671 (3)

⊕⊝⊝⊝
VERY LOW 1 2 3

downgraded for study limitations, heterogeneity and indirectness

Number reaching target Hb

Study population

RR 0.95
(0.84 to 1.07)

687 (3)

⊕⊝⊝⊝
VERY LOW 1 2 3

downgraded for study limitations, heterogeneity and indirectness

916 per 1000

870 per 1000
(769 to 980)

Moderate

895 per 1000

850 per 1000
(752 to 957)

Number of deaths

Study population

RR 0.95
(0.33 to 2.75)

724 (3)

⊕⊕⊝⊝
LOW 1 4

downgraded for study limitations, imprecision

22 per 1000

21 per 1000
(7 to 62)

Moderate

26 per 1000

25 per 1000
(9 to 72)

Adverse events: RBC transfusions

Study population

RR 1.26
(0.53 to 2.98)

470 (2)

⊕⊕⊝⊝
LOW 1 4

downgraded for study limitations, imprecision

38 per 1000

48 per 1000
(20 to 114)

Moderate

35 per 1000

44 per 1000
(18 to 103)

Adverse events: hypertension

Study population

RR 1.02
(0.62 to 1.69)

724 (3)

⊕⊕⊕⊝
MODERATE 1

downgraded for study limitations

70 per 1000

72 per 1000
(44 to 119)

Moderate

62 per 1000

63 per 1000
(38 to 104)

Adverse events: arteriovenous complications

Study population

RR 1.02
(0.39 to 2.68)

724 (3)

⊕⊕⊝⊝
LOW 1 4

downgraded for study limitations, imprecision

26 per 1000

26 per 1000
(10 to 68)

Moderate

23 per 1000

24 per 1000
(9 to 62)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; Hb: haemoglobin; RBC: red blood cells

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 two of the three studies had unclear allocation concealment

2 surrogate outcome

3 unexplained heterogeneity

4 small numbers with wide confidence intervals

Figures and Tables -
Summary of findings 2. Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis
Summary of findings 3. Epoetin theta versus epoetin beta in CKD patients not receiving dialysis

Epoetin theta versus epoetin beta in CKD patients not receiving dialysis

Patient or population: anaemia in predialysis patients
Intervention: epoetin theta
Comparison: epoetin beta

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with epoetin beta

Risk with Epoetin theta

Final Hb

The mean final Hb was 0 g/dL

The mean final Hb in the intervention group was 0.02 g/dL lower (0.25 g/dL lower to 0.21 g/dL higher)

288 (1)

⊕⊕⊕⊝
MODERATE 1

downgraded for indirectness ‐ surrogate outcomes

Mean weekly epoetin dose

The mean weekly epoetin dose was 0 units/week

The mean weekly epoetin dose in the intervention group was 0.4 units per week higher (5.68 units per week lower 6.48 units/week higher)

288 (1)

⊕⊕⊝⊝
LOW 1 2

downgraded for indirectness ‐ surrogate outcomes and imprecision

Deaths

Study population

RR 2.46
(0.29 to 20.77)

288 (1)

⊕⊕⊝⊝
LOW 2

downgraded for imprecision

11 per 1000

26 per 1000
(3 to 219)

Moderate

11 per 1000

26 per 1000
(3 to 218)

Adverse events: hypertension

Study population

RR 0.35
(0.11 to 1.08)

288 (1)

⊕⊕⊕⊝
MODERATE 2

downgraded for imprecision

74 per 1000

26 per 1000
(8 to 80)

Moderate

74 per 1000

26 per 1000
(8 to 80)

Adverse events: RBC transfusions

Study population

RR 1.48
(0.06 to 36.10)

288 (1)

⊕⊕⊝⊝
LOW 2

downgraded for imprecision

0 per 1000

0 per 1000
(0 to 0)

Adverse events: discontinuation of therapy

Study population

RR 1.77
(0.68 to 4.63)

288 (1)

⊕⊕⊝⊝
LOW 2

downgraded for imprecision

53 per 1000

93 per 1000
(36 to 244)

Moderate

53 per 1000

93 per 1000
(36 to 244)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; RBC: red blood cells

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 Surrogate outcome, not a patient‐centred outcome

2 Small numbers, wide confidence intervals

Figures and Tables -
Summary of findings 3. Epoetin theta versus epoetin beta in CKD patients not receiving dialysis
Comparison 1. Epoetin alpha every 2 weeks versus weekly

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in haemoglobin level Show forest plot

4

785

Mean Difference (IV, Random, 95% CI)

‐0.20 [‐0.33, ‐0.07]

2 Number reaching target haemoglobin Show forest plot

4

798

Risk Ratio (M‐H, Random, 95% CI)

0.96 [0.93, 0.99]

3 Number of deaths Show forest plot

4

838

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.38, 2.07]

4 Adverse events Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

4.1 RBC transfusions

3

580

Risk Ratio (M‐H, Random, 95% CI)

1.56 [0.71, 3.45]

4.2 Hypertension

4

838

Risk Ratio (M‐H, Random, 95% CI)

0.85 [0.55, 1.32]

4.3 Thrombovascular events

4

838

Risk Ratio (M‐H, Random, 95% CI)

1.41 [0.67, 3.00]

4.4 Adverse events leading to discontinuation of therapy

1

258

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.20, 4.79]

Figures and Tables -
Comparison 1. Epoetin alpha every 2 weeks versus weekly
Comparison 2. Epoetin alpha every 4 weeks versus every 2 weeks

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in haemoglobin level Show forest plot

3

671

Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.43, 0.10]

2 Number reaching target haemoglobin Show forest plot

3

687

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.84, 1.07]

3 Number of deaths Show forest plot

3

724

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.33, 2.75]

4 Adverse events Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

4.1 RBC transfusions

2

470

Risk Ratio (M‐H, Random, 95% CI)

1.26 [0.53, 2.98]

4.2 Hypertension

3

724

Risk Ratio (M‐H, Random, 95% CI)

1.02 [0.62, 1.69]

4.3 Arteriovenous complications

3

724

Risk Ratio (M‐H, Random, 95% CI)

1.02 [0.39, 2.68]

Figures and Tables -
Comparison 2. Epoetin alpha every 4 weeks versus every 2 weeks
Comparison 3. Epoetin alpha different doses given three times weekly

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Final haemoglobin Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

1.1 100 U/kg versus 50 U/kg

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

1.2 150 U/kg versus 50 U/kg

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2 Mean arterial BP Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

2.1 100 IU/kg/wk versus 50 IU/kg/wk

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2.2 150 IU/kg/wk versus 50 IU/kg/wk

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3 Final creatinine levels Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

3.1 100 IU/kg/wk versus 50 IU/kg/wk

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

3.2 150 IU/kg/wk versus 50 IU/kg/wk

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Figures and Tables -
Comparison 3. Epoetin alpha different doses given three times weekly
Comparison 4. Epoetin alpha different doses given every four weeks

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Final haemoglobin Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

2 Number reaching target haemoglobin Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

3 Number of deaths Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

4 Adverse events Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

4.1 Hypertension

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

4.2 Thrombovascular events

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

4.3 RBC transfusions

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

Figures and Tables -
Comparison 4. Epoetin alpha different doses given every four weeks
Comparison 5. Epoetin alpha IV versus subcutaneous administration

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Final haemoglobin Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

Figures and Tables -
Comparison 5. Epoetin alpha IV versus subcutaneous administration
Comparison 6. Epoetin theta versus epoetin beta

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Final Hb Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

2 Mean weekly epoetin dose Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

3 Deaths Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

4 Adverse events Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

4.1 Hypertension

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

4.2 RBC transfusions

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

4.3 Discontinuation of therapy

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

Figures and Tables -
Comparison 6. Epoetin theta versus epoetin beta